Renal Cell Carcinoma

NASHVILLE, Tenn. — A fully automated artificial intelligence approach predicted post-nephrectomy glomerular filtration rate with comparable accuracy as validated clinical prediction models, according to study results.

MADRID — MEDI5752, a novel bispecific antibody binding to CTLA-4 and PD-1, showed potential as a first-line treatment in patients with advanced clear cell renal cell carcinoma, according to data presented at ESMO Congress.

NASHVILLE, Tenn. — Patients with renal cell carcinoma who met eligibility criteria for pivotal phase 3 trials achieved significantly longer survival after combination immunotherapy than trial-ineligible patients, according to study results.

NASHVILLE, Tenn. — Adjuvant pembrolizumab appeared well tolerated among patients with high-risk renal cell carcinoma after nephrectomy, according to study results.

NASHVILLE, Tenn. — Fewer than one in 20 patients with kidney cancer who meet guidelines for genetic evaluation received genetic counseling, according to findings presented at International Kidney Cancer Symposium: North America.

NASHVILLE, Tenn. — Zanzalintinib monotherapy showed promising antitumor activity among patients with previously treated clear cell renal cell carcinoma, according to findings presented at International Kidney Cancer Symposium: North America.

NASHVILLE, Tenn. — Alexander Kutikov, MD, FACS, received Kidney Cancer Association’s Andrew C. Novick Award.

NASHVILLE, Tenn. — An analysis of germline susceptibility to renal cell carcinoma revealed considerable heterogeneity, according to findings presented at International Kidney Cancer Symposium: North America.

NASHVILLE, Tenn. — Belzutifan exhibited efficacy at two doses for patients with advanced clear cell renal cell carcinoma, according to randomized phase 2 study results presented at International Kidney Cancer Symposium: North America.

NASHVILLE, Tenn. — Pavlos Msaouel, MD, PhD, received the Kidney Cancer Association’s Christopher G. Wood Rising Star Award.